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ABSTRAK
Studi ini merupakan tinjauan pustaka dengan mengambil data dari literature-literatur dan jurnal yang 
berhubungan dengan faktor-faktor risiko kanker prostat meliputi umur, ras, riwayat keluarga, insulin-Like growth 
factor, penyakit menular seksual, obesitas, kebiasaan merokok, konsumsi alkohol,vasektomi, gaya hidup, diet, 
lingkungan, paparan pekerjaan. Untuk metode pencegahan kanker prostat meliputi kacang kedelai, likopen, 
the hijau, suplemen, dan olah raga.
Berbagai penelitian epidemiologi telah menghubungkan resiko kanker prostat dengan  faktor-faktor antara 
lain umur, ras, riwayat keluarga, insulin like-growth factor, gaya hidup, diet, lingkungan dan paparan pekerjaan. 
Hasil-hasil dari penelitian epidemiologi tersebut, secara in vivo, in vitro, dan studi klinis awal menunjukkan 
peran  dari produk-produk makanan dan suplemen  terhadap pencegahan kanker prostat. Dalam hal ini, 
masih diperlukan penelitian lebih lanjut untuk mencari lebih luas faktor-faktor resiko dan metode  pencegahan 
berkembangnya kanker prostat. Hal ini penting bagi para klinisi untuk memasukkan informasi-informasi ini 
sebagai bahan edukasi untuk mengurangi risiko dan mencegah kanker prostat.
Kata kunci: kanker prostat, PCa, faktor risiko, pencegahan
ABSTRACT
This is a literature review study. Data was obtained from several literature reviews and journal resources 
that have correlation with the risk factors involved in PCa including age, ethnicity, family history, insulin-Like 
growth factor, sexually transmitted disease, obesity, smoking, alcohol consumption, vasectomy, and diet, and 
the prevention of PCa including soy, lycopene, green tea, supplementation, and exercise.
Numerous epidemiologic studies have linked PCa risk to various factors, i.e. age, ethnicity, family 
history, insulin like-growth factors, lifestyle, diet, environmental and occupational exposures. The results 
of epidemiological, In vivo, in vitro, and early clinical studies suggested that selected dietary products and 
supplementation may play a role in PCa prevention. More studies are still needed to explore and find the risk 
factors and preventive methods of PCa development. It is important for clinician to ellaborate these informations 
for education to lower PCa risks and prevent PCa. 
Keywords: prostate cancer, PCa, risk factor, prevention.
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INTRODUCTION
Prostate cancer (PCa) which defined by 
National Cancer Institute (NCI) as cancer that 
forms in tissues of the prostate. The incidence 
of PCa is rising worldwide due to demographic 
factors, increasing of elderly population, and 
number of cases identified following prostate 
specific antigen (PSA) testing. American Cancer 
Society (ACS) estimated that in the year 2012 
there were about 241,740 new cases of PCa and 
28,170 men died from PCa. PCa occurs mainly 
in older men, nearly two thirds was diagnosed in 
men age 65 or older. The average range of age 
at the time of PCa diagnosis is between 60 until 
70 years and about 1 men in 6 will be diagnosed 
with PCa during his lifetime.1
In Indonesia PCa incidence currently 10.3 per 
100,000 population, which has increased almost 
threefold in the last decade.2 Data from WHO in 
Global Cancer Statistics (GLOBOCAN) cancer 
project 2008 have been shown that mortality 
rates are generally high in predominantly black 
populations (Caribbean, 26.3 per 100,000 and 
sub-Saharan Africa, ASRs 18-19 per 100,000), 
lower in Asia (ASR 2.5 per 100,000 in Eastern 
Asia), Europe and Oceania.2,3
African-American men have a higher 
incidence rate and at least twice mortality rate 
compared with men from other race/ethnic group 
caused by genetic susceptibility. Men with one 
family history of PCa are twice more likely to 
develop the disease, while those with two or 
more relatives are nearly four times as likely to 
get PCa. The risk is even higher if the affected 
family members were diagnosed before age of 
65.2,4 The other possible risk factor including 
life style factors such as diet (animal fat, meat, 
milk and dairy products), supplementation intake 
(Vitamin D, Calcium), sunlight exposure, job 
related chemical exposure, smoking, obesity, 
alcohol consumption, level of physical activity, 
men with a history of vasectomy. It has also been 
suggested that socioeconomic factors, sexual 
activity and sexually transmitted infections may 
influence the probability of developing PCa or 
being diagnosed with PCa.2
The purpose of this review is to know and 
understand the risk factors and preventive 
measures in PCa. These risk factors need to 
be recognized and managed properly in order 
to choose the right treatment option, minimize 
adverse effects and loss of prevent quality of life. 
Clinicians need to determine whether patients are 
at high or low risk of PCa.
RISK FACTOR OF PROSTATE CANCER 
Age
Older men are more likely to be diagnosed with 
high risk PCa and have lower overall survival. As 
a result, age often plays a role in treatment choice.5 
This risk increases significantly after the age of 50 
in white men who have no family history of the 
disease and after the age of 40 in black men and 
men who have a close relative with PCa. Table 1 
shows the percentage of men who will have PCa 
over different time periods. Therefore, it is highly 
recommended for older men to get digital rectal 
examination (DRE) and prostate specific antigen 
(PSA) testing screening.5,6
Table 1. Percent of US. men who develop PCa over 10-, 
20-, and 30-year intervals according to their current age, 
2008–2010†
Current 
Age 10 Years 20 Years 30 Years
30 0.01 0.35 2.54
40 0.34 2.57 8.18
50 2.31 8.12 13.73
60 6.41 12.59 14.92
70 7.73 10.64 N/A
Adapted from SEER Cancers Statistics Review 1975-2012
Study in Cancer of the Prostate Strategic 
Urologic Research Endeavor (CaPSURE) tried 
to investigate comprehensive risk of PCa.7 
High-risk patients were identified by using the 
validated Cancer of the Prostate Risk Assessment 
(CAPRA) score. Competing risks regression was 
used to identify the independent impact of age on 
cancer survival among older men with high-risk 
disease. The results showed 26% of men of age 
75 years old presented with high-risk disease 
(CAPRA score 6 to 10).3
Ethnicity
Recent studies suggest that ethnicity are 
essential risk factor of PCa.7 African American 
men, West African ancestry from the Caribbean 
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and South American men have a higher incidence 
and mortality of PCa than white men. The lowest 
incidence of PCa is typically found in Asian men, 
associated not only with genetic susceptibility 
but also with the diet, lifestyle and environmental 
factors.8-10
Data from the National Cancer Institute 
has shown that African American males PCa 
(54.2/100 000 vs 24.7/100 000) considerably 
higher than other ethnic races.4 Chromosome 
8q24 variants have been reported to be associated 
with PCa risk and are more common in African 
American men. Some studies have also shown a 
higher rate of variations in cell apoptosis genes 
such as BCL2 and tumor suppression genes such 
as EphB2 in African American men.8,11
The evidence of relationship between genetic 
component to the high incidence and mortality rate 
in African American men came from epidemiologic 
studies with similar genetic backgrounds.8,9 The 
analysis implies that PCa in African American 
is biologically and genetically more aggressive 
compared with European American.8 Kyle et al 
have found that African American men without 
PCa significantly had higher PSA levels than 
white man in all age groups. Vijayakumar et al 
also found higher serum PSA levels in African 
American with newly diagnosed localized PCa 
than European American.9,10
Family History
Family history of PCa is well established risk 
factor for PCa risk in men.12 Zheng et al showed 
five single-nucleotide polymorphisms have been 
identified as having a significant association with 
PCa when present together with a family history 
of PCa.13
Health Professional Follow-Up Study, 
followed up 3,695 patients with PCa from 
1986 to 2004 and found that there was a 
2.3-fold increased risk of PCa with a family 
history of PCa in both a father and a brother 
(95% confidence interval (CI) = 1.76–3.12). 
Furthermore, that study reported a 2.16- and 
1.95-fold increased PCa risk when the father or 
brother was diagnosed with PCa at <60 and 60 
years of age, respectively. An increased risk of 
early onset PCa occurring at age <65 years was 
evident in men with a family history of PCa 
(OR = 2.25, 95% CI = 1.95 – 2.60). Three meta-
analyses have confirmed the association between 
family history of PCa and risk of PCa in men. It 
has been proposed that there may be a hereditary 
component to PCa risk. This has been attributed 
to genes in 7 different loci. Although the role 
played by these genes in the development of PCa 
is unknown, it is estimated that they contribute 
to less than 5–10% of the disease risk.13,14
Linkage studies using genetic markers to 
search for chromosomal regions that show 
excessive sharing of inherited alleles in cancer 
affected families have been helpful in identifying 
important cancer susceptibility genes in other 
cancers. Advances in biogenetics have allowed 
identifying the numerous allelic low penetrance 
mutations denominated genetic polymorphisms, 
which are involved in the rest of familial forms 
of PCa. Some authors attribute up to 40% of all 
PCa to genetic factors. The highest risk is caused 
by the involvement of the hereditary factors 
as mentioned in Table 2, which increase the 
neoplastic transformation of prostate epithelial 
cells.13
Insulin-Like Growth Factors
Insulin-like growth factor (IGF-I), a 
polypeptide with mitotic and antiapoptotic 
effects.1 It has demonstrated to play a crucial 
role in PCa biology and to be implicated in both 
mitogenic and anti-apoptotic events in PCa cell 
lines.15
The Insulin-Like Growth Factor family 
involves the combination of two ligands (IGF-I 
and IGF-II), two receptors (IGF-IR and IGF-
IIR), six high-affinity binding proteins (IGFBPs 
1–6), a large group of IGFBP proteases and a 
new group of proteins, which is low-affinity 
IGFBP-related proteins (IGFBP-rPs). Members 
of this family form a network of interactions both 
among themselves and with other GF families 
and their signalling pathways.16
Several studies have related serum levels of 
IGF-I to PCa risk, both among cases and controls, 
and some of these studies, but not others, have 
shown a direct association between IGF-I and 
cancer risk. One of the most informative studies 
is a prospective nested case-control investigation 
of 152 PCa patients and controls derived from the 
Physicians’ Health Study. Elevated serum IGF-I 
could be observed in men at least 5 years prior to 
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European population, high circulating IGF-I 
concentration is positively associated with risk 
for PCa over the short and long term, circulating 
IGF-I concentration was associated with a 
significant increased risk for PCa [OR for highest 
vs. lowest quartile, 1.69; 95% confidence interval 
(CI), 1.35-2.13; P(trend) = 0.0002].17,18
Sexually Transmitted Disease (STD)
Several epidemiologic studies have suggested 
that factors related to sexual behaviour and STDs 
may be associated with PCa. In 1990, McNicol 
and Dodd reported that HPV type 16 and 18 are 
present in normal and cancer tissues of human 
prostate.19 Since 1990, many studies have detected 
high-risk HPVs in PCa tissues by Southern Blot 
and/or polymerase chain reaction (PCR) analysis. 
It conclude that infection and subsequent 
inflammation in the prostate is speculated to be 
several microorganisms that cause prostatitis 
or sexually transmitted infections may be an 
important risk factor in the pathogenesis of PCa. 
Approximately 13 published studies looked for 
the presence of HPVs in prostate carcinomas. 
These investigations revealed that the presence 
of these viruses vary from 4.2% to 53%.19,20
Meta analysis from Taylor et al examined 
the current epidemiological evidence for 
the association between specific STD and 
PCa. Significant elevated ORs for PCa were 
demonstrated for any STDs (1.48, 95% confidence 
interval [CI] 1.26-1.73), gonorrhea (1.35, 95% 
CI 1.05-1.83), and human papillomavirus (1.39, 
95% CI 1.12-2.06). This meta-analysis provides 
evidence of a higher rate of PCa in men with a 
history of an exposure to gonorrhea, HPV, or 
any STD.19,20
Stark et al suggest men who had been 
infected with the STD trichomoniasis were only 
slightly more likely to develop PCa years later, 
compared to men with no documented evidence 
of prior infection, they were nearly three times 
as likely to die of the disease once they had 
PCa. The finding suggests that infection may 
make PCa more aggressive and more likely to 
progress. This large prospective case control 
study obtained further support for an association 
between a seropositive status for antibodies 
against Trichomonas vaginalis and the risk of 
PCa, with statistically significant associations 
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the diagnosis of PCa.15,16 Clinical and pathologic 
parameters were correlated with IGF-1 receptor 
intensity and frequency of staining.16 Only 
2–3 staining on a scale of 0–3 was considered 
positive in this evaluation. These data show that 
the IGF-1 receptor is expressed in PCas and 
node metastases. The data showed that stromal 
expression of the receptor is associated with 
higher Gleason score support the hypothesis that 
there is an association between IGF-1 receptor 
and a more aggressive tumor phenotype. In the 
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identified for the risk of extraprostatic PCa and 
for clinically relevant, potentially lethal PCa.21
Obesity
Obesity is suspected to be a risk factor for 
aggressive PCa due to its associations with altered 
circulating levels of metabolic and sex steroid 
hormones involved in prostate development as 
well as oncogenesis.22 It was hypothesized that 
underlying the relationship between adiposity 
and tumor development involve adiposity 
related changes in metabolism and endogenous 
hormone levels.2 An important specific metabolic 
consequence of obesity, particularly when 
combined with physical inactivity, is a reduced 
tissue response to insulin, especially in terms of 
reduced uptake of glucose. This insulin resistance 
leads to chronically elevated blood levels of 
insulin, which is a growth-enhancing hormone 
and thus is a biologically plausible risk factor for 
cancer development and progression.23
One possible explanation for the lower risk of 
PCa diagnosis among obese men is that cancers 
may be more difficult to detect.24,25 Consequently, 
obese men are less likely to have an elevated 
PSA, less likely to undergo a biopsy, and thus less 
likely to be diagnosed with PCa, moreover obese 
men have larger prostate size making cancer 
detection at biopsy more difficult.25 Because 
obesity is a potential factor leading to lower 
detection of PCa, clinicians should consider 
Body Mass Index (BMI) when interpreting PSA 
concentration, Inclusion of BMI along with other 
factors that are currently included (race, rectal 
screening, and family history) in the existing 
PCa risk calculator, improve its performance.26
Three meta analyses reported a positive 
association between obesity and PCa incidence. 
The relative risks (RRs) in these studies 
were modest yet consistent, from 1.01 (95% 
confidence interval [CI], 1.0–1.02) per 1 kg/m2 
increase in BMI to 1.05 (95% CI, 1.01–1.08) and 
1.03 (95% CI, 1.0–1.07) per 5 kg/m2 increment 
in BMI.24 Data from three National Survey 
that present study linking evidence from 3 large 
nationally representative samples of the US 
population notes that obesity is associated with 
higher PCa progression and mortality despite an 
association with lower prostate ca incidence.26
Smoking
Tobacco and cigarette smoke contains over 
4,000 chemicals, among which more than 60 are 
listed as class 1 or class 2 carcinogens according 
to the International Agency for Research on 
Cancer (IARC).27 However, constituents of 
cigarette smoke, such as polycyclic aromatic 
hydrocarbons (PAH), required metabolic 
activation, evasion of detoxification processes, 
and subsequent binding to DNA to exert their 
carcinogenic action. Therefore, functional 
polymorphisms in genes involved in PAH 
metabolism and detoxification may modify the 
effect of smoking on PCa.28 An association with 
smoking could also have a hormonal basis: male 
smokers were found to have elevated levels of 
circulating androsterone and testosterone, which 
may increase PCa risk or contribute to cancer 
progression.27,29,30
A meta-analysis from Huncharek et al27 
with 24 prospective cohort studies evaluated 
the relationship between smoking and PCa. The 
studies enrolling 21579 PCa case participants 
for a general variance-based meta-analysis. 
Results. In the pooled data, current smokers had 
no increased risk of incident PCa (RR=1.04; 95% 
CI=0.87-1.24), but it was stratified by amount of 
smoking. It had statistically significant elevated 
risk (cigarettes per day or years: RR=1.22; 
95% CI=1.01, 1.46; pack years of smoking: 
RR=1.11; 95% CI=1.01, 1.22). Former smokers 
had an increased risk (RR=1.09; 95% CI=1.02, 
1.16). Current smokers had an increased risk of 
fatal PCa (RR=1.14; 95% CI=1.06, 1.19). The 
heaviest smokers had a 24% to 30% greater 
risk of death from PCa than did nonsmokers. 
This observational cohort studies showed an 
association of smoking with PCa incidence and 
mortality.27,29
Most studies examining relationship between 
smoking and PCa recurrence or PCa related 
mortality demonstrated that smoking related to 
an increasing in PCa recurrence and mortality, 
even after controlling for multiple factors 
including the more advanced malignant disease 
at presentation. Gutt et al reported follow-up data 
from 434 patients after external-beam radiation 
therapy with curative intent. In patients who 
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had been current smokers at the time of therapy, 
they found a recurrence rate 5.2 times greater 
than the rate of life-long nonsmokers, and in 
former smokers, the recurrence rate was 2.9 
times greater.30
Alcohol Consumption
Alcohol consumption is one of the most 
important risk factors for human cancers, but also 
potentially one of the largest avoidable factors. 
Alcohol consumption is generally measured in 
drinks per day, with a “typical” drink of alcohol 
containing about 15 g of ethanol irrespective 
of the type of beverage consumed (beer, wine 
and liquor, straight or mixed). Alcohol use, and 
particularly heavy use, may be a possible risks 
factor of cancers including prostate.31
Evidence suggests that the effect of alcohol is 
modulated by polymorphisms in genes encoding 
enzymes for ethanol metabolism (e.g. alcohol 
dehydrogenases), folate metabolism and DNA 
repair.32
Dennis et al reported that there was a 
significant relationship between higher PCa risk 
and higher number of alcohol intake. It showed 
that RR of PCa risk increased from 1,05 for one 
alcoholic drink per day to 1,21 for four alcoholic 
drinks per day.33,34
Vasectomy
Vasectomy is the most frequent of male 
contraception in the United States, with 
approximately 500,000 procedures performed 
annually. It has been associated in some studies 
with increased PCa risk.35 There is no proven 
biological mechanism that might explain an 
association between vasectomy and PCa has been 
identified. In studies demonstrating small relative 
risks, data were limited by methodological 
shortcomings and potential biases, including 
detection and misclassification bias.36
Diet
1. Saturated animal fat
A high calorie intake of saturated animal fat 
has often been associated with an increased risk 
of PCa due to increasing testosterone levels.37-39
Mucci et al, Platz et al and Pauwels et al 
concluded that animal fat consumption per capita 
are positively associated with the incidence 
and mortality of PCa. The studies revealed a 
relation between fat intake and advanced PCa 
with OR=1.6-2.9.38
A recent case control population based 
study in patients ≤60 years found a statistically 
significant PCa risk comparing high and low 
intake of total fat to PCa risk with OR = 2.53 (CI 
95%: 1.72-3.74), saturated fat with OR = 2.49 (CI 
95%: 1.69-3.66), monounsaturated fat with OR 
= 2.69 (CI 95%: 1.82-3.96), and polyunsaturated 
fat with OR = 2.34 (CI 95%: 1.59--3.46).40
The possible biological mechanisms involved 
between saturated animal fat and PCa risks are the 
following: (a) high energy intake increases basal 
metabolism and insulin growth factors, tumor 
proliferation, (b) lipid metabolism generates 
free radicals, leukotrienes, prostaglandins, 
(c) promotes prostate carcinogenesis via 
androgen.41,42
2. Meat (red, smoked, and seasoned)
Meat has been related to carcinogenesis as 
observed in the high correlations between per 
capita meat consumption and cancer incidence 
and mortality.43
World Research Cancer and Fund (WCRF) 
study showed that consumption of <500 g of red 
meat per week (OR = 0.77; 95% CI: 0.61, 0.98) 
was significant predictor of decreased risk of a 
highly aggressive Pca. Recent studies directly 
associate the high intake of these varieties 
of meat with risk of PCa and PCa mortality. 
Cooking at elevated temperature (125-300oC) 
causes the formation of mutagenic heterocyclic 
amines.38,39,43
Rohman et al40 showed that men consuming 
≥5 servings/week of processed meat had higher 
risk of PCa compared with men who eat ≤1 
servings/week.44 Similarly, high consumption 
of red meats increased PCa risk among black 
men in U.S.
3. Calcium, Milk and Dairy Products
Milk and dairy products contribute to the 
increase of saturated animal fats level as it 
provides high calcium content.40A meta-analysis 
of 12 publications showed that men with high 
dairy intake (RR=1.11; CI 95%: 1.00-1.22) and 
calcium (RR=1.39; CI 95%: 1.09-1.77) had 
significant higher risks of PCa than men with 
lower dietary intake, as well as in aggressive 
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cases (RR=1.33; CI 95%: 1.00-1.78) and 
(RR=1.46; CI 95%: 0.65-3.25), respectively.41,43 
Dairy products, significantly increased the risk of 
PCa when compared with those who consumed 
the most versus the least; a 63%, 53%, and 52% 
increased risk, respectively.45,46
There is a biological possibility for the 
role for calcium in prostate carcinogenesis. 
Intracellular calcium pools have been shown 
to control PCa cell growth and susceptibility 
to apoptosis. Therefore, small alterations in 
calcium homeostasis could result in increased 
proliferation, differentiation, and apoptosis in 
PCa cells.47,48
PREVENTION OF PROSTATE CANCER 
Soy
Soy, containing protein and phytoestrogens, 
has been identified as dietary component that may 
play an important role in reducing the incidence 
of PCa.49 The family of phytoestrogens is 
composed of four classes such as isoflavones, 
flavonoids, coumestans, and lignans. In soy, 
the primary isoflavone correlated with PCa is 
genistein and biochanin-A.50
Genistein has been shown to exhibit potent 
anti-proliferative effect on various cancers. The 
study indicates that genistein consumption is 
associated with a lower incidence of clinical 
PCa metastasis through its effect on PCa cell 
invasion inhibition. Meta analyses of the two 
studies including men with identified risk of 
prostate cancer found a significant reduction in 
PCa diagnosis following administration of soy 
isoflavones (RR = 0.49, 95%CI 0.26, 0.95).50,51
Lycopene
Lycopene is a bright red phytochemical in the 
carotenoid family that have potent antioxidant 
properties.
The Health Professional Follow-up Study 
documented that 2-4 servings of tomato sauce 
per week were associated with a 35% reduction 
of PC risk.52 Giovannucci et al highlighted 
the reduction in PCa risk associated with both 
tomato product consumption and lycopene 
intake in a large, multicenter cohort of health 
professionals. From five major carotenoids, 
only lycopene intake was associated with 
reduced risk (RR=0.79, 95% CI=0.64-0.99, for 
high versus low quintile of intake). A phase II 
randomized clinical trial of 15 mg of lycopene 
supplementation twice daily for 3 weeks before 
radical prostatectomy exhibited a decrease in the 
plasma IGF-I levels with no significant changes 
in Bax and Bcl-2.52,53
Lycopene and other carotenoids have a 
number of cancer-preventive biological effects 
including (a) inhibition of growth and induction 
of differentiation in prostate cancer (b) up-
regulation of connexin 43 (Cx43) and increased 
gap junctional intercellular communication, and 
(c) prevention of oxidative DNA damage.54,55
Green Tea (EGCG)
Based on epidemiological data the incidence 
of Pca is very low in East Asian countries where 
green tea is a highly consumed beverage. This 
might be explained partly by the fact that oral 
consumption of green tea polyphenols containing 
one of the catechins called epigallocatechin-3-
gallate (EGCG) that has chemopreventive effects 
in PCa experimental models.56,57
Administration of a green tea polyphenol 
infusion (0.1% in drinking water) to the 
Transgenic Adenocarcinoma of the Mouse 
Prostate (TRAMP) mice for 24 weeks markedly 
inhibited PCa development and distant site 
metastases.56,57
It has been suggested that EGCG in green 
tea possesses the most potent activity against 
all stages of multistage carcinogenesis. After 
supplementation of EGCG, plasma concentration 
has increased up to 4,400 pmol/mL, enough to 
exert antioxidant activity in the blood stream.56-58
Nam et al reported that EGCG potently 
and specifically inhibits the chymotrypsin-
like activity of the proteasome in vitro (50% 
inhibitory concentration [IC 50] = 86–194 
nmol/L) at the concentrations found in the serum 
of green tea drinkers.58
Supplementation
a. Vitamin E
Vitamin is a main liposoluble antioxidant of 
the human organism with additional anti PCa 
effects.59,50 Vitamin E consists of tocopherols 
and tocotrienols. Tocopherols are the major 
source of vitamin E in the diet.The relationship 
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between vitamin E nutrition and PCa risk 
has been investigated in many epidemiologic 
studies. It showed controversial result, which 
7 of 14 case control studies showed an inverse 
association between dietary or blood levels of 
tocopherols and PCa risks.61,62 α-tocopherols 
supplementation was found to be significantly 
associated with lower incidence of PCa (as 
a secondary endpoint), and higher serum 
α-Tocopherol was associated with a reduced 
risk of PCa.59,62 These results encouraged the 
launching of the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT).59,61,62
b. Vitamin D
Vitamin D acts as a regulatory hormone 
for multiple cell activities in the human body. 
The activated form of vitamin D is 1,25-OH2 
vitamin D can potentially play a role in cancer 
pathogenesis.63,64
John et al. demonstrated a significant inverse 
association between UVR and PCa risk.64 Barnett 
et al. collected data from cancer registries 
of several countries that were categorized as 
sunny or less sunny. It was found that the risk 
of secondary solid cancer after melanoma was 
significantly lower in sunny countries compared 
with less sunny countries. It concluded that 
vitamin D production in the skin reduced the risk 
of several solid tumors, including PCa.63
 Ma et al. Found an inverse association 
was observed between vitamin D receptor 
polymorphisms and PCa risk in men with 
low serum vitamin D levels, strengthened by 
Tuohimaa et al.63,65-67
Shui et al conclude Higher 25(OH)D levels 
were associated with a 57% reduction in the risk 
of lethal PCa (OR=0.43, 95% CI=0.24-0.76).67
c. Selenium (Se)
Selenium concentration is accumulated in 
plants (cereals, legumes, and tubers) and animals 
(eggs, meat, fish, and seafood). The trace element 
selenium used to be treated as a very toxic 
substance, but modern science now regards it as 
essential but in small quantities.67
Epidemiologic studies show lower mortality 
of PCa in countries and regions with soils 
rich in selenium (Se). Meta-analysis of 16 
epidemiological studies (11 cohorts and 5 case-
controls) documents PCa risk reductions between 
16%-28% when comparing high to low selenium 
consumption.68 Another systematic review and 
meta analysis from The World Cancer Research 
Fund/American Institute for Cancer Research 
Continuous Update Project database with 12 
studies including total of 13,254 participants 
and 5007 cases of PCa. The relationship between 
serum selenium and PCa in meta-analysis 
showed that the risk decreased with increasing 
plasma/serum selenium up to 170 ng/mL.69
Exercise
Exercise is one of the modified lifestyle 
therapy that appear to offer many benefits and 
relatively few side effects. Lack of exercise has 
also been linked to increased PCa risk. Antonelli 
et al found that veterans who exercised were 
significantly less PCa risks.70
Several studies showed that physically 
active PCa patients have significantly greater 
quality of life, less fatigue, and lower PSA 
levels and delay in initiating ADT by two years 
compared with less active PCa peers. They 
also have significantly lower serum insulin and 
insulin-like growth factor (IGF-1), higher IGF 
binding protein (IGFBP-1), and a lower risk of 
high-grade disease (Gleason score 7 or greater) 
compared with less active PCa patients.70
CONCLUSION
Numerous epidemiologic studies have linked 
PCa risk to various factors, i.e. age, ethnicity, 
family history, insulin like-growth factors, 
lifestyle, diet, environmental and occupational 
exposures. The results of epidemiological, 
In vivo, in vitro, and early clinical studies 
suggested that selected dietary products and 
supplementation may play a role in PCa 
prevention. More studies are still needed to 
explore and find the risk factors and preventive 
methods of PCa development. It is important 
for clinician to ellaborate these informations for 
education to lower PCa risks and encourage PCa 
prevention.
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